Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-12-09
1998-12-22
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514464, A61K 3136, A61K 3134
Patent
active
058520520
ABSTRACT:
The invention refers to the treatment and prevention of lyso paf-mediated disorders with an effective amount of at least one antagonists against lyso paf receptors. Lyso paf or paf receptor antagonists were administered with or without an antagonist against production of ether phospholipids. Lyso paf antagonists are Ginkgoloides which are administered, for example, by food or topically.
REFERENCES:
patent: 4183912 (1980-01-01), Rosenthale
patent: 4571407 (1986-02-01), Chatterjee et al.
patent: 4582824 (1986-04-01), Nishikawa et al.
patent: 4595693 (1986-06-01), Biftu et al.
patent: 4621083 (1986-11-01), Casals-Stenzel et al.
patent: 4734280 (1988-03-01), Braquet
patent: 4900729 (1990-02-01), Stransky et al.
patent: 5147864 (1992-09-01), Wissner et al.
patent: 5202313 (1993-04-01), Bombardelli et al.
patent: 5334592 (1994-08-01), Billah
patent: 5356791 (1994-10-01), Korth
Lowry et al., J. Biol. Chem. 193 (1951), pp. 265-274, "Protein Measurement with the Folin Phenol Reagent".
Benveniste et al., J. Exp. Med. 136 (1972), pp. 1356-1377, "Leukocyte-Dependent Histamine Release from Rabbit Platelets".
Vadas et al., J. Immunology 122 (1979), pp. 1228-1235, "A new Method for the Purification of Human Eosinophils and Neutrophils, and a Comparison of the Ability of these Cells to Damage Schistosomula of Schistosoma mansoni".
Demopoulos et al., J. Biol. Chem. vol. 254, No. 19 (1979), pp. 9355-9358, "Platelet-Activating Factor".
Benveniste et al., C.R. Acad. Science (Paris) 289 (1979), pp. 1037-1377, "Semi-synthese et structuro proposee du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine".
Bourgain et al., Journal of Pharmacologie 14 (Suppl.), 1983, p. 26, FED Proc. 46(3) R. Korth p. 44, Mar. 1987, "Effects of PAF-Acether on Platelet-Vessel Wall Interaction".
Bjork et al., Acta Physio Scand 1983, pp. 305-308, "PAF-acether (Platelet-Activating Factor) Increases Microvascular Permeability and Affects Endothelium-Granulocyte Interaction in Microvascular Beds".
Camussi et al., Journal de Pharmacologie 14 (Suppl.), 1983, p. 10, "Release of Platelet-Activating Factor from Human Endothelial Cells".
Record et al., Forum de Cancerologie (1984), p. 223, "Implication du facteur activant les plaquettes (PAF-acether) dans le phenomene de dissemination metastatique?".
Kornecki et al., Science, vol. 226, No. 4681 (1984), pp. 1454-1456, "Platelet-Activating Factor-Induced Aggregation of Human Platelets Specifically Inhibited by Triazolobenzodiazepines".
Hwang et al., Biochemical and Biophysical Research Communications, vol. 128, No. 2 (1985) pp. 972-979, "Specific Binding Sites for Platelet Activating Factor in Human Lung Tissues".
Etienne et al., Agents and Actions vol. 17, No. 3/4 (1985) pp. 368-370, "In Vivo inhibition of plasma protein leakage and Salmonella enteritidis -- induced mortality in the rat by a specific paf-acether antagonist: BN 52021".
Braquet et al., Blood and Vessel, 16 (1985), pp. 585-572, "BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonists isolated from Ginko bilboa L".
G. Grynkiewicz et al., The Journal of Biological Chemistry, vol. 260, No. 6, Mar. 25, 1985, pp. 3440-3450, "A New Generation of Ca.sup.2- Indicators with Greatly Improved Fluorescence Properties".
R.H. Bourgain et al., New Horizons in Platelet Activating Factor Research, Oct. 15-18, 1985, No. 60, p. 78, "PAF-Acether Antagonists in Experimental Arterial Thrombosis".
T. Doebber et al., Bochemical and Biophysical Research Communications, vol. 127, No. 3, Mar. 29, 1985, pp. 799-808, "Platelet Activating Factor (PAF) Involvement in Endotoxin-Induced Hypotension in Rats. Studies with PAF-Receptor Antagonist Kadsurenonc".
L. Maes et al., Pharmacological Research Communications, vol. 18, Suppl., 1986, pp. 81-89, "Endogenic PACF-Acether Production by Guinea Pig Endothelial Cells in Experimental Arterial Thrombosis".
M. Sanchez Crespo et al., Pharmacological Research Communications, vol. 18, Suppl., 1986, pp. 181-197, "Evidence of a Role for PAF-Acether in the Pathophysiology of the Shock State".
D. Handley et al., Drug Development Research, vol. 7, 1986, pp. 361-375, "Platelet Activating Factor and Inflammation in Atherogenesis: Targets for Drug Development".
N. Tanaka et al., Invasion Metastasis vol. 6, 1986, pp. 209-224, "Platelet-Aggregating Activities of Metastasizing Tumor Cells".
G. Grignani et al., Haematologica, vol. 71, pp. 245-255, 1986, "The Possible Role of Blood Platelets in Tumour Growth and Dissemination".
D. Nunez et al., European Journal of Pharmacology, vol. 123, 1986, pp. 197-205, "Specific Inhibition of PAF-Acether-Induced Platelet Activation by BN 52021 and Comparison with the PAF-Acether Inhibitors Kadsurenone and CV 3988".
R. Korth et al., Thrombosis Research, vol. 41, 1986, pp. 699-706, "Unsaturated Platelet-Activating Factor: Influence on Aggregation, Serotonin Release and Thromboxane Synthesis of Human Thrombocytes".
B. Arnoux et al., Inhibition by Ketotifen.sup.1-4, Sep. 23, 1987, pp. 855-860, "Accumulation of Platelets and Eosinophils in Baboon Lung After PAF-Acether Challenge".
R. Korth et al., European Journal of Pharmacology, vol. 142, 1987, pp. Binding to Intact Human Platelets".
R. Korth et al., 71st Annual Meeting of the Federation of American Societies for Experimental Biology, Mar. 29-Apr. 2, 1987, "Comparison of Human Endothelial Cells in Culture and Platelets for Tritium PAF-Acether Binding".
B. Spinnewyn et al., IHB Reserach Labs, Robinson, France, Sep. 1987, vol. 34, No. 3, pp. 337-349, "Involvement of Platelet-Activating Factor (PAF) in Cerebral Post-Ischemic Phase in Mongolian Gerbils".
E.R. Pettipher et al., Agents and Actions, vol. 2, 1/2 1987, pp. 98-103, "PAF-Acether in Chronic Arthritis".
E. Ninio, New Horizons in Platelet Activating Factor Research, 1987, pp. 27-35, "Regulation of Platelet Activating Factor-Acether Biosynthesis in Various Cells Types".
J. Casals-Stenzel et al., L.J. Pharmacology, vol. 90, 1987, pp. 139-146, "Triazolodiazepines:Dissociation of Their PAF (Platelet Activating Factor) Antanogistic and CNS Activity".
R. Korth et al., European Journal of Pharmacology, vol. 152, 1988, pp. 101-110, "Comparison of Three PAF-Acether Receptor Antagonist Ginkgolides".
A. Fradin et al., Biochimica et Biophysica Acta, vol. 963, Jun. 9, 1988, pp. 248-257, "Inhibition of Eicosanoid and PAF Formation by Dexamethasone in Rat Inflammatory Polymorphonuclear Neutrophils May Implicate Lipocortin `s`".
E. Kornecki et al., Science, vol. 240, Jun. 24, 1988, pp. 1792-1794, "Neuroregulatory and Neuropathological Actions of the Ether-Phospholipid Platelet-Activating Factor".
H. Malech et al., The New England Journal of Medicine, vol. 317, No. 11, Sep. 10, 1988, pp. 687-694, "Medical Intelligence Current Concepts: Immunology Neutrophils in Human Diseases".
T. Otamiri et al., Clinical Research Centre and Departments of Surgery, Clinical Chemistry, and Occupational Medicine, University Hospital, Linkoping, Sweden, Gut, vol. 29, 1988, pp. 489-494, "Phospholipase A.sub.2 Inhibition Prevents Mucosal Damage Associated with Small Intestinal Ischaemia in Rats".
J. Benveniste et al., Federation of European Biochemical Societies, vol. 226, No. 2, Jan. 1988 pp. 371-376, "Preformed PAF-Acether and Lyso PAF-Acether are Bound to Blood Lipoproteins".
R. Palmantir et al., Biochemical and Biophyscial Research Communications, vol. 162, No. 1, Jul. 14, 1989, pp. 475-482, "Biosynthesis of PAF-Acether XIV. PAF-Acether Output in Murine Peritoneal Macrophages is Regulated by the Level of Acetylhydrolase".
R. Korth et al., Br. J. Pharmacology, vol. 98, 1989, pp. 653-661, "Interaction of the PAF Antagonist WEB 2086 and its Hetrazepine Analogues with Human Platelets and Endothelial Cells".
M. Lekka et al., Biochimica et Biophysica Acta, vol. 1042, 1990, pp. 217-220, "In Vivo Metabolism of Platelet-Activating-Factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by the Protozoan Tetrahymena Pyriformis".
R. Feliste et al., Atherosclerosis, vol. 78, Aug. 1989, pp. 151-158, "Protective Effect of BN 52021, a Speci
Criares Theodore J.
Korth Ruth
LandOfFree
Treatment of lyso paf-mediated mental or neuronal disorders with does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of lyso paf-mediated mental or neuronal disorders with, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of lyso paf-mediated mental or neuronal disorders with will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2048102